Is the serum creatinine/cystatin C ratio a new predictive marker in neurocritically ill people?

Takeaway

  • The serum creatinine (Cr)/cystatin C (CysC) ratio is a predictor of long-term poor clinical outcome in neurocritically ill people.

Why this matters

    Sarcopenia, age-related loss of muscle mass, occurs in 60–70% of neurocritically ill people. New data reveal that the Cr/CysC ratio, indicative of sarcopenia, may be a more suitable prognostic indicator compared with imaging techniques, however, further validation studies are required.